Next Article in Journal
Treatment of Extra — Abdominal Desmoid Tumors with Chemotherapy
Next Article in Special Issue
New Approaches to Immunotherapy for HPV Associated Cancers
Previous Article in Journal
Prevention of Prostate Cancer with Oleanane Synthetic Triterpenoid CDDO-Me in the TRAMP Mouse Model of Prostate Cancer
Previous Article in Special Issue
Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans
Article Menu

Export Article

Open AccessReview
Cancers 2011, 3(3), 3370-3393;

Novel Antibody-Based Proteins for Cancer Immunotherapy

Laboratorio de Patología Celular y Molecular, Centro de Medicina Experimental, Instituto Venezolano de Investigaciones Científicas. Caracas, 1020-A, Venezuela
Authors to whom correspondence should be addressed.
Received: 28 July 2011 / Revised: 12 August 2011 / Accepted: 15 August 2011 / Published: 19 August 2011
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
View Full-Text   |   Download PDF [298 KB, uploaded 19 August 2011]


The relative success of monoclonal antibodies in cancer immunotherapy and the vast manipulation potential of recombinant antibody technology have encouraged the development of novel antibody-based antitumor proteins. Many insightful reagents have been produced, mainly guided by studies on the mechanisms of action associated with complete and durable remissions, results from experimental animal models, and our current knowledge of the human immune system. Strikingly, only a small percent of these new reagents has demonstrated clinical value. Tumor burden, immune evasion, physiological resemblance, and cell plasticity are among the challenges that cancer therapy faces, and a number of antibody-based proteins are already available to deal with many of them. Some of these novel reagents have been shown to specifically increase apoptosis/cell death of tumor cells, recruit and activate immune effectors, and reveal synergistic effects not previously envisioned. In this review, we look into different approaches that have been followed during the past few years to produce these biologics and analyze their relative success, mainly in terms of their clinical performance. The use of antibody-based antitumor proteins, in combination with standard or novel therapies, is showing significant improvements in objective responses, suggesting that these reagents will become important components of the antineoplastic protocols of the future. View Full-Text
Keywords: PMNs; NK-cells; T-cells; radioimmunoconjugates; immunocytokines; antibody fusion protein; immunotherapy; antibody-drug conjugates; combinatorial strategies PMNs; NK-cells; T-cells; radioimmunoconjugates; immunocytokines; antibody fusion protein; immunotherapy; antibody-drug conjugates; combinatorial strategies
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Fuenmayor, J.; Montaño, R.F. Novel Antibody-Based Proteins for Cancer Immunotherapy. Cancers 2011, 3, 3370-3393.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top